Back to search results

CoreMap EP Mapping System for Persistent Atrial Fibrillation

This study is testing a new medical device called the CoreMap EP Mapping System for people with persistent atrial fibrillation (AF), a type of irregular heartbeat. The CoreMap system helps doctors understand your heart's electrical activity (endocardial mapping) and guide a procedure called ablation to correct the irregular rhythm. The study aims to see how safe and effective the CoreMap system is. For some participants, it will compare the CoreMap system to standard care. To join, you must be between 18 and 80 years old and have persistent or long-standing persistent AF. The study will look at how well the treatment works after 6 and 12 months. The study is currently recruiting 245 participants.

Study design
This is a global, multi-site study that will enroll 245 participants. It has three phases, with some phases comparing the CoreMap system to a control group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be checked at 7 days, and then again at 6 and 12 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06529978

Endocardial Mapping With the CoreMap EP Mapping System

Recruiting
NAAges 18–80InterventionalTreatment
CoreMap Inc.
~245 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:CoreMap EP Mapping System MappingCoreMap EP Mapping System Map-Guided Ablation

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phases 1 and Phase 2 Primary Endpoint:
Measured over 7 days
+1 more outcome measured

Conditions

Persistent Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT06529978

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Na Homolce Hospital

    Praha Klanovice, Czechiano site contact published

    Recruiting

  • NCH Downtown Baker Hospital

    Naples, Floridano site contact published

    Enrolling by invitation

  • University of Vermont Medical Center

    Burlington, Vermontno site contact published

    Enrolling by invitation

  • Virginia Commonwealth University (VCU)

    Richmond, Virginiano site contact published

    Enrolling by invitation

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sarah Kalil · STUDY_DIRECTOR · CoreMap Inc.

Who to contact

Jim Foster, SysEng
[email protected]
6178723908
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Phases 1 and Phase 2 Primary Endpoint:7 days

    Incidence of study device related serious adverse events within seven (7) days of the study procedure.

  • Phase 2 and Phase 3 Primary Effectiveness Endpoint:6 and 12 months

    Freedom from documented recurrence of AF, atrial tachycardia (AT), or atrial flutter (AFL) based on electrocardiographic data through a 12-month follow-up and excluding a 90-day blanking period.